The FDA and Sarepta: A window into the world of drug regulation - STAT

The FDA and Sarepta: A window into the world of drug regulation - STAT

Opinion: The FDA and Sarepta: a window into the real world of drug regulation

By MATTHEW HERDER

RUBY WALLAU FOR STAT

The FDA's decisons about Exondys 51 and Vyondys 53, both developed by Sarepta Therapeutics, offer a rare glimpse into the world of drug regulation.

READ MORE